Two decades of successes and failures in controlling the transmission of HIV through injecting drug use in England and Wales, 1990 to 2011

Eurosurveillance

Volumn 19, Issue 14, 2014, Pages

  Hope, V D ^a,b   Harris, R J ^a   De Angelis, D ^c   Croxford, S ^a   Marongiu, A ^a   Parry, J V ^a   Ncube, F ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c MRC BIOSTATISTICS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; COLONOSCOPY; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; EPIDEMIC; FEMALE; GASTROENTERITIS; GENDER; HEMOLYTIC UREMIC SYNDROME; HUMAN; LABORATORY DIAGNOSIS; MALE; MIDDLE AGED; QUESTIONNAIRE; SEROTYPE; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; DRUG USERS; ENGLAND; FEMALE; HEALTH SURVEYS; HIV INFECTIONS; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PREVALENCE; QUESTIONNAIRES; RISK FACTORS; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; WALES; YOUNG ADULT;

EID: 84898454284     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2014.19.14.20762     Document Type: Article

References (77)

1. Des Jarlais DC, Friedman SR, Choopanya K Vanichseni S, Ward TP. International epidemiology of HIV and AIDS among injecting drug users. AIDS. 1992;6(10):1053-68. http://dx.doi.org/10.1097/00002030-199210000-00001
2. Ghys PD, Bazant W, Monteiro MG, Calvani S, Lazzari S. The epidemics of injecting drug use and HIV in Asia. AIDS. 2001:15(Suppl 5):S91-9 http://dx.doi.org/10.1097/00002030-200100005-00012
3. Rhodes T, Lowndes C, Judd A, Mikhailova LA, Sarang A, Rylkov A, et al. Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russian Federation: Implications for HIV prevention. AIDS. 2002;16(13):F25-31. http://dx.doi.org/10.1097/00002030-200209060-00002
4. Aceijas C, Stimson GV, Hickman M, Rhodes T; United Nations Reference Group on HIV/AIDS Prevention and Care among IDU in Developing and Transitional Countries. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS. 2004;18(17):2295-303. http://dx.doi.org/10.1097/00002030-200411190-00010
5. Van Ameijden, Coutinho RA. Maximum impact of HIV prevention measures targeted at injecting drug users. AIDS. 1998;12(6):625-33. http://dx.doi.org/10.1097/00002030-199806000-00012
6. MacDonald M, Wodak AD, Ali R, Crofts N, Cunningham PH, Dolan K, et al. HIV prevalence and risk behaviours in needle exchange attenders: a national study. Med J Aust. 1997;166(5):237-40.
7. Crofts A, Aitken CK. Incidence of blood borne virus infection and risk behaviours in a cohort of injecting drug users in Victoria. Med J Aust. 1997;167(1):17-20.
8. Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet. 1997;349(9068):1797-800. http://dx.doi.org/10.1016/S0140-6736(96)11380-5
9. Stimson GV. AIDS and injecting drug use in the United Kingdom, 1987-1993: The policy response and the prevention of the epidemic. Soc Sci Med. 1995;41(5):699-716. http://dx.doi.org/10.1016/0277-9536(94)00435-V
10. Robertson JR, Bucknall AB, Welsby PD, Roberts JJ, Inglis JM, Peutherer JF, et al. Epidemic of AIDS related virus (HTLV-III/LAV) infection among intravenous drug abusers. Br Med J. 1986;292(6519):527-9. http://dx.doi.org/10.1136/bmj.292.6519.527
11. Hope VD, Judd A, Hickman M, Sutton A, Stimson GV, Parry JV, et al. HIV prevalence among Injecting Drug Users in England & Wales 1990 to 2003: Evidence for increased transmission in recent years. AIDS. 2005;19(11):1207-14. http://dx.doi.org/10.1097/01.aids.0000176222.71355.a1
12. Hope VD, PA Rogers, L Jordan, T Paine, S Barnett, JV Parry, et al. Sustained increase in the sharing of needles and syringes among drug users in England and Wales. AIDS. 2002;16(18):2494-6. http://dx.doi.org/10.1097/00002030-200212060-00022
13. Judd A, Hickman M, Jones S, McDonald T, Parry JV, Stimson GV, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London-prospective cohort study. BMJ. 2005;330(7481):24-5. http://dx.doi.org/10.1136/bmj.38286.841227.7C
14. Noone A, Durante AJ, Brady AR, Majid F, Swan AV, Parry JV, et al. HIV infection in injecting drug users attending centres in England and Wales, 1990-1991. AIDS. 1993;7(11):1501-7. http://dx.doi.org/10.1097/00002030-199311000-00015
15. Judd A, Parry J, Hickman M, McDonald T, Jordan L, Lewis K, et al. Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. J Med Virol. 2003;71(1):49-55. http://dx.doi.org/10.1002/jmv.10463
16. Connell JA, Parry JV, Mortimer PP, Duncan J. Novel assay for the detection of immunoglobulin G anti-human immunodeficiency virus in untreated saliva and urine. J Med Virol. 1993;41(2):159-64. http://dx.doi.org/10.1002/jmv.1890410212
17. Davies C, English L, Lodwick A, McVeigh J, Bellis MA, editors. UK Focal Point on Drugs. United Kingdom Drug Situation: Annual Report to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2009. Chapter 13. ISSN 1609-6150. London: Department of Health; October 2009. Available from:http://www.nta.nhs.uk/uploads/2009.pdf
18. Sweeting MJ, Hope VD, Hickman M, Parry JV, Ncube F, Ramsay ME, et al. Hepatitis C infection among injecting drug users in England and Wales (1992-2006): there and back again? Am J Epidemiol. 2009;170(3):352-60. http://dx.doi.org/10.1093/aje/kwp141
19. Burnham KP, Anderson DR. Formal inference from more than one model: multimodel inference (MMI). In: Model selection and multimodel inference: A practical information theoretic approach. 2nd ed. New York: Springer-Verlag; 2002. p.149-205. ISBN 0-387-95364-7.
20. Keiding N. Age specific incidence and prevalence: a statistical perspective (with discussion). J R Statist Soc A. 1991;154(3):371-412. http://dx.doi.org/10.2307/2983150
21. Ades AE, Nokes DJ. Modeling age-and time-specific incidence from seroprevalence: toxoplasmosis. Am J Epidemiol. 1993; 137(9):1022-34.
22. Welton NJ, Ades AE. A model of toxoplasmosis incidence in the UK: evidence synthesis and consistency of evidence. J R Statist Soc C. 2005;54(2):385-404. http://dx.doi.org/10.1111/j.1467-9876.2005.00490.x
23. Health Protection Agency (HPA), Health Protection Scotland, Public Health Wales, and Public Health Agency Northern Ireland. Shooting Up: Infections among people who inject drugs in the UK 2011. An update: November 2012. London: HPA; 2012. Available from:http://www.hpa.org.uk/Publications/InfectiousDiseases/BloodBorneInfections/ShootingUp/1211Shootingup2012/
24. Judd A, Hickman M, Hope VD, Sutton AJ, Stimson GV, Gill ON, et al. Impact of twenty years of selective hepatitis B vaccination: is hepatitis B declining among injecting drug users in England and Wales? J Viral Hepat. 2007;14(8):584-91. http://dx.doi.org/10.1111/j.1365-2893.2007.00844.x
25. Jones JA, Salmon JE, Djuretic T, Nichols G, George RC, Gill ON, on behalf of an investigating team. An outbreak of serious illness and death among injecting drug users in England and Wales during 2000. J Med Microbiol. 2002;51(11):978-84.
26. Health Protection Agency (HPA), Health Protection Scotland, National Public Health Service for Wales, CDSC Northern Ireland, CRDHB, and the UASSG. Shooting Up-Infections among injecting drug users in the United Kingdom 2005-An update: October 2006. London: HPA; 2006. ISBN 0 901144 86 X. Available from:http://www.hpa.org.uk/Publications/InfectiousDiseases/BloodBorneInfections/ShootingUp/0610ShootingUpInfectionsamongIDUs2005/
27. Advisory Council on the Misuse of Drugs. AIDS and drug misuse. Part 1. London: Department of Health; 1988.
28. Evaluation of syringe exchange schemes. Circular EL(89) P/81. London: Department of Health; 1989.
29. Tackling drugs together. A strategy for England 1995-1998. London: Stationery Office; 1995.
30. Secretary of State for Health. The Health of the Nation: a strategy for health in England. London: Stationery Office; 1992.
31. Stimson GV. 'Blair declares war': the unhealthy state of British drug policy. Int J Drug Policy. 2000;11(4):259-264. http://dx.doi.org/10.1016/S0955-3959(00)00060-8
32. The United Kingdom Anti-Drugs Co-ordinator. Tackling drugs to build a better Britain: the governments ten-year strategy for tackling drug misuse. London: Stationery Office; 1998.
33. Unlinked Anonymous Surveys Steering Group. Prevalence of HIV in the United Kingdom 1998: data to the end of 1998. London: Department of Health; 1999.
34. Hope VD, Judd A, Hickman M, Lamagni T, Hunter G, Stimson GV, et al. Prevalence of hepatitis C virus in current injecting drug users in England and Wales: is harm reduction working? Am J Public Health. 2001;91(1):38-42. http://dx.doi.org/10.2105/AJPH.91.1.38
35. Better prevention, better services, better sexual health-The national strategy for sexual health and HIV. London: Department of Health; 2001. Available from:http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4003133
36. Models of care for the treatment of drug misusers. London: National Treatment Agency for Substance Misuse; 2002. ISBN 0-9544534-0-9. Available from: http://www.nta.nhs.uk/uploads/nta_modelsofcare2_2002_moc2.pdf
37. Update Drugs Strategy. London: Home Office; 2002. ISBN 1-84082-9397.
38. Hickman M, Hope VD, Brady T, Madden P, Jones S, Honour S, et al. Hepatitis C (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. J Viral Hepat. 2007;14(9):645-52. http://dx.doi.org/10.1111/j.1365-2893.2007.00855.x
39. Rhodes T, Briggs D, Kimber J, Holloway G, Jones S. Groin injecting and vein care in the context of crack and 'speedball' injection: Qualitative study. Addiction. 2007;102(11):1782-90. http://dx.doi.org/10.1111/j.1360-0443.2007.01969.x
40. De Angelis D, Hickman M, Yang S. Estimating long-term trends in the incidence and prevalence of opiate/injecting drug use and the number of ex-users: the use of back-calculation methods and opiate overdose deaths. Am J Epidemiol. 2004;160(10):994-1004. http://dx.doi.org/10.1093/aje/kwh306
41. Hope VD, Hickman M, Tilling K. Capturing crack-cocaine use: Estimating the prevalence of Crack-cocaine use in London using capture-recapture with covariates. Addiction. 2005;100(11):1701-8. http://dx.doi.org/10.1111/j.1360-0443.2005.01244.x
42. Hickman M, Higgins V, Hope VD, Bellis M, Tilling K, Walker A, et al. Injecting drug use in Brighton, Liverpool, and London: best estimates of prevalence and coverage of public health indicators. J Epidemiol Community Health. 2004;58(9):766-71. http://dx.doi.org/10.1136/jech.2003.015164
43. Statistics for drug treatment activity in England 2005/06 from the National Drug Treatment Monitoring System. London: National Treatment Agency for Substance Misuse; 2006. Available from:https://www.ndtms.net/Reports.aspx (permissions required).
44. Health Protection Agency (HPA), SCIEH, National Public Health Service for Wales, CDSC Northern Ireland, CRDHB, and the UASSG. Shooting Up-Infections among injecting drug users in the United Kingdom 2002-An update: December 2003. London: HPA; 2003. ISBN 0 901144 62 2. Available from:http://www.hpa.org.uk/Publications/InfectiousDiseases/BloodBorneInfections/ShootingUp/0312ShootingUpInfectionsamongdrugusers/
45. Models of care for the treatment of adult drug misusers: Update 2006. London: National Treatment Agency for Substance Misuse; 2006. MOC3. Available from:www.nta.nhs.uk/uploads/nta_modelsofcare_update_2006_moc3.pdf
46. Reducing drug-related harm: An action plan. London: Department of Health; 2007. Available from:http://webarchive.nationalarchives.gov.uk/20080910134953/dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_074850
47. Drugs: protecting families and communities: The 2008 drug strategy. London: HM Government; 2008. ISBN 978-1-84726-615-3. Available from:http://webarchive.nationalarchives.gov.uk/20100419081707/http:/drugs.homeoffice.gov.uk/publication-search/drug-strategy/drug-strategy-2008
48. Harm Reduction Works. London: National Treatment Agency for Substance Misuse. [Accessed: 27 Mar 2014]. Available from: http://www.harmreductionworks.org.uk/
49. Needle and syringe programmes: providing people who inject drugs with injecting equipment. Public Health Guidance, PH18. London: National Institute for Health and Care Excellence (NICE); 2009. Available from:http://guidance.nice.org.uk/PH18
50. Methicillin resistant Staphylococcus aureus (MRSA) in injecting drug users. CDR Weekly. 2003;13(27). 3 Jul 2003. Available from:http://webarchive.nationalarchives.gov.uk/+/http://www.hpa.org.uk/cdr/archives/2003/cdr2703.pdf
51. Drug strategy 2010. Reducing demand, restricting supply, building recovery: supporting people to live a drug free life. London: HM Government; 2010. ISBN: 978-1-84987-388-8. Available from:https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/98026/drug-strategy-2010.pdf
52. Royston P. A strategy for modelling the effect of a continuous covariate in medicine and epidemiology. Stat Med. 2000;19(14):1831-47. http://dx.doi.org/10.1002/1097-0258(20000730)19:14<1831::AID-SIM502>3.0.CO;2-1
53. Rhodes T, Davis M, Judd A. Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Addiction. 2004;99(5):621-33. http://dx.doi.org/10.1111/j.1360-0443.2004.00692.x
54. Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis. 2006;6:93. http://dx.doi.org/10.1186/1471-2334-6-93
55. Vickerman P, Hickman M, May M, Kretzschmar M, Wiessing L. Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction. 2010;105(2):311-8. http://dx.doi.org/10.1111/j.1360-0443.2009.02759.x
56. de Vos AS, van der Helm JJ, Prins M, Kretzschmar ME. Determinants of persistent spread of HIV in HCV-infected populations of injecting drug users. Epidemics. 2012;4(2):57-67. http://dx.doi.org/10.1016/j.epidem.2012.01.001
57. Sanchez AY, Aerts M, Shkedy Z, Vickerman P, Faggiano F, Salamina G, et al. A mathematical model for HIV and hepatitis C co-infection and its assessment from a statistical perspective, Epidemics. 2013;5(1):56-66. http://dx.doi.org/10.1016/j.epidem.2013.01.002
58. M Hickman, Hope V, Brady T, Madden P, Jones S, Honor S, et al. Hepatitis C (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. J Viral Hepat. 2007;14(9):645-52. http://dx.doi.org/10.1111/j.1365-2893.2007.00855.x
59. Center for Disease Control (CDC). Pneumocystis pneumonia--Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30(21):250-2.
60. Health Protection Agency. HIV in the United Kingdom: 2011 Report. London: Health Protection Services, Colindale; 2011. Available from: http://www.hpa.org.uk/webc/hpawebfile/hpaweb_c/1317131685847
61. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre HT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983;220(4599);868-71. http://dx.doi.org/10.1126/science.6189183
62. Sarngadharan MG, Popovic M, Brunch L, Schupbach J, Gallo RC. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science. 1984;224(4648):506-8. http://dx.doi.org/10.1126/science.6324345
63. Cheingsong-Popov R, Weiss RA, Dalgleish A, Tedder RS, Shanson DC, Jeffries DJ, et al. Prevalence of antibody to human T-lymphotropic virus type III in AIDS and AIDS-risk patients in Britain. Lancet. 1984;2(8401):477-80. http://dx.doi.org/10.1016/S0140-6736(84)92562-5
64. Mortimer PP, Jesson WJ, Vandervelde EM, Pereira MS. Prevalence of antibody to human T lymphotropic virus type III by risk group and area, United Kingdom 1978-84. Br Med J (Clin Res Ed). 1985;290(6476):1176-8. http://dx.doi.org/10.1136/bmj.290.6476.1176
65. Mortimer PP, Parry JV, Mortimer JY. Which anti-HTLV III/LAV assays for screening and confirmatory testing? Lancet. 1985;2(8460):873-7. http://dx.doi.org/10.1016/S0140-6736(85)90136-9
66. Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, Durack DT, et al. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986;1(8481):575-80. http://dx.doi.org/10.1016/S0140-6736(86)92808-4
67. AIDS (Control) Act 1987. London: Stationery Office; 1987. ISBN 0 10 543387 X. Available from:http://www.legislation.gov.uk/ukpga/1987/33/enacted
68. Parry JV, Perry KR, Mortimer PP. Sensitive assays for viral antibodies in saliva: an alternative to tests on serum. Lancet. 1987;2(8550):72-5. http://dx.doi.org/10.1016/S0140-6736(87)92737-1
69. Advisory Council on the Misuse of Drugs. AIDS and drug misuse update. London: Stationery Office; 1993.
70. Majid A, Holmes R, Desselberger U, Simmonds P, McKee TA. Molecular epidemiology of hepatitis C virus infection amongst intravenous drug users in rural communities. J Med Virol. 1995;46(1):48-51. http://dx.doi.org/10.1002/jmv.1890460111
71. Cooper DA and Merigan TC. Clinical treatment. AIDS. 1996;10(Suppl A):S133-4. http://dx.doi.org/10.1097/00002030-199601001-00018
72. Unlinked Anonymous Surveys Steering Group. Prevalence of HIV in England and Wales, data to the end of 1996. London: Department of Health, Public Health Laboratory Service, Institute of child health; 1997.
73. Tackling drugs to build a better Britain: The government's ten-year strategy for tackling drug misuse. London: Department of Health; 1998. Available from:http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4006530
74. Tackling crack: a vational plan. London: Home Office; 2002. Available from:http://www.drugscope.org.uk/Resources/Drugscope/Documents/PDF/Good%20Practice/NationalCrackPlan.pdf
75. Tackling substance misuse in Wales-a partnership approach. Cardiff: National Assembly for Wales; 2000. ISBN 0 7504 2438 9.
76. National Treatment Agency for Substance Misuse (NTA). London: Home Office. [Accessed: 27 Mar 2014]. Available from:http://webarchive.nationalarchives.gov.uk/20100407120701/drugs.homeoffice.gov.uk/treatment/strategy/nta/
77. Hepatitis C action plan for England. London: Department of Health; 2004 Available from:http://webarchive.nationalarchives.gov.uk/20130107105354/http://dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4084713.pdf